Automated electronic health record-based screening for Fabry disease in unexplained left ventricular hypertrophy (FAPREV-HCM)

Authors

Institutions

Publication Details

Journal
Open Heart
Published
2025-01-01
DOI
https://doi.org/10.1136/openhrt-2024-003116
Citations
3
Primary Topic
Lysosomal Storage Disorders Research
Type
article
Field-Weighted Citation Impact
3.49

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Automated electronic health record-based screening for Fabry disease in unexplained left ventricular hypertrophy (FAPREV-HCM)

Claudia Sommer, Lora Lorenz, Christoph Wanner, Peter Nordbeck et al.
3 citations
Open Heart
Lysosomal Storage Disorders Research
3.49
article

Automated electronic health record-based screening for Fabry disease in unexplained left ventricular hypertrophy (FAPREV-HCM)

Claudia Sommer, Lora Lorenz, Christoph Wanner, Peter Nordbeck, Nurcan Üçeyler, Kolja Lau, Georg Fette, Victoria Sokalski
article en
3 citations

Abstract

No abstract available for this paper.
Open HeartVol. 12(1)
Universitätsklinikum Würzburg (DE)
Amgen, Eli Lilly and Company, AstraZeneca, Sanofi, Alexion Pharmaceuticals, Amicus Therapeutics, Novo Nordisk, Idorsia Pharmaceuticals
Openalex Percentile: Top 9%
Lysosomal Storage Disorders Research
3.49
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.